News | May 19, 2022
WHO validates Convidecia vaccine for Covid-19
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants
The single-dose vaccine has been approved in China, Mexico, Ecuador, Chile, Argentina, Hungary, Kirghizstan, Pakistan, Indonesia and Malaysia
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
Subscribe To Our Newsletter & Stay Updated
